Products
Datopotamab Deruxtecan Biosimilar Antibody-Drug Conjugate (TROP-2) for Research
Cat No.: GMP-Bios-INN-796
Pre-made Datopotamab Deruxtecan benchmark antibody (Whole mAb ADC, anti-TACSTD2 therapeutic antibody, Anti-EGP-1/EGP1/GA733-1/GA7331/GP50/M1S1/TROP2 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-796-1mg | 1mg | |
| GMP-Bios-INN-796-10mg | 10mg | |
| GMP-Bios-INN-796-100mg | 100mg | |
| GMP-Bios-INN-796-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Datopotamab Deruxtecan Biosimilar, Whole Mab Adc, Anti-Tacstd2 Antibody: Anti-EGP-1/EGP1/GA733-1/GA7331/GP50/M1S1/TROP2 therapeutic antibody Drug Conjugate |
| INN Name | Datopotamab Deruxtecan |
| Target | TACSTD2 |
| Format | Whole mAb ADC |
| Derivation | Humanized |
| Species Reactivity | human |
| CH1 Isotype | IgG1 - kappa |
| VD LC | IgG1 - kappa |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Daiichi Sankyo Inc. (Edison NJ USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
About target - TACSTD2
1. Protein Tumor-associated calcium signal transducer 2
2. Gene TACSTD2
3. Organism Homo sapiens (Human)
Function
May function as a growth factor receptor.
